

## 3 Questions to....

...Tjiana Sustercic from Steinbeis  
Advanced Risk Technologies Institute  
doo Kragujevac




### **What has been most surprising and challenging for you related to your involvement in PANBioRA so far?**

Most **surprising** was how well each developed in-silico model fitted the puzzle in the big picture of organ-on-a-chip investigation. Also very interesting was how the in-vitro experiments supplement and help in-silico results to be more accurate and vice versa.

It is always **challenging** how to combine the methods and results from in-vitro experiments with the in-silico numerical models. But there was a very helpful communication between the partners and the exchange of information was frequent and effective.

### **How would you describe PANBioRA in one sentence?**

An ambitious project that will provide solutions for a more intelligent way of selecting the most suitable biomaterial for potential implants.



Model of Bioreactor ©Sartik

### **From your point of view: What will be the biggest impact of PANBioRA?**

The biggest impact of PANBioRa is a unique integrated system for biomaterial risk assessment that comprises of multidisciplinary protocols and procedures.

Learn more about SARTIK and their involvement in PANBioRA!





## Steinbeis Advanced Risk Technologies Institute doo Kragujevac

Steinbeis Advanced Risk Technologies Institute doo Kragujevac ([SARTIK](#)) was founded in March 2015 in Kragujevac, Serbia as the branch of Steinbeis Transfer Institute Advanced Risk Technologies, Stuttgart, Germany.

The main activities of SARTIK include professional certification and degree programmes in different engineering areas as well as work in the domain of research and development, professional expertise and consultancy.

### **Role in PANBioRA:**

SARTIK will be in charge of the multi-scale modelling applied to biomaterials. Further, necessary models for the assessment of the data coming from the integrated system will be developed.

In cooperation with partner BioSys and R-Tech, SARTIK will take part in the development of web-tools, preclinical validation of the system as well as risk analysis and assessment..

